Newron Pharmaceuticals S.p.A.
XETRA NP5.DE
Newron Pharmaceuticals S.p.A. Debt to Equity Ratio for the year ending December 31, 2023: -1.62
-
Newron Pharmaceuticals S.p.A. Debt to Equity Ratio for the year ending December 31, 2022 was -3.25, a -123.47% change year over year.
-
Newron Pharmaceuticals S.p.A. Debt to Equity Ratio for the year ending December 31, 2021 was 13.87, a 807.68% change year over year.
-
Newron Pharmaceuticals S.p.A. Debt to Equity Ratio for the year ending December 31, 2020 was 1.53, a 232.88% change year over year.
-
Newron Pharmaceuticals S.p.A. Debt to Equity Ratio for the year ending December 31, 2019 was 0.46, a 9,019.04% change year over year.
| Date | Debt to Equity Ratio | Debt to Income Ratio | Debt to Tangible Net Worth Ratio | Dividend Coverage Ratio |
|---|
Don’t Miss A Beat
| CEO | Mr. Stefan Weber |
| IPO Date | July 4, 2019 |
| Location | Italy |
| Headquarters | via Ludovico Ariosto 21 |
| Employees | 22 |
| Sector | Healthcare |
| Industries | |
Newron Pharmaceuticals SpA operates as a biopharmaceutical company. The company is headquartered in Bresso, Milano and currently employs 24 full-time employees. The company focuses on the discovery and development of pharmaceutical products. The firm is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The firm undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.
Past 5 years
StockViz Staff
February 6, 2025
Any question? Send us an email